Navigation Links
Disruption of nerve cell supply chain may contribute to Parkinson's
Date:5/12/2011

New data offer hints to why Parkinson's disease so selectively harms brain cells that produce the chemical dopamine, say researchers at Washington University School of Medicine in St. Louis.

Dopamine is involved in brain cell communications including the signals that control movement. As Parkinson's kills the dopamine-producing cells, patients begin to develop tremors, problems moving and other symptoms.

The new research shows that a drug known to damage dopamine-producing nerve cells and mimic Parkinson's disease does so by rapidly damaging cellular energy generators called mitochondria. This damage impairs the ability of mitochondria to circulate around the cell as they normally would. As a result, axons, the extended arms nerve cells use to send messages, wither; a few days later, the body or main portion of the cell also dies.

"Much of the research into Parkinson's disease treatments is focused on saving the bodies of these cells, but our results suggest that keeping axons healthy also is essential,"says Karen O'Malley, PhD, of Washington University School of Medicine in St. Louis. "When axons die back, dopamine is no longer delivered to the neurons that need it. The cell body also has fewer connections to other cells, and it needs those connections to survive."

The results were published May 11 in The Journal of Neuroscience.

Many processes and facilities for cellular maintenance are in the body of the nerve cell, and their products sometimes have to travel a significant distance to reach the axon's end.

"If you think, for example, about one of your peripheral nerves, the cell body is located in the spinal column, but some of the axons extend as far as your big toe," says O'Malley, professor of neurobiology. "That's like the cell body sits in an office in St. Louis and the end of the axon is in Chicago."

O'Malley compares the axon's system for transporting supplies to a railroad. Mitochondria are part of the railroad's cargo. They supply the energy that allows the axon to do its work.

For the study, O'Malley gave cultured mouse nerve cells a toxin called MPP+ that causes Parkinson's-like symptoms.

"MPP+ is a derivative of a synthetic form of heroin developed in California in the early 1980s," O'Malley says. "It came to scientists' attention when teenage abusers of the drug went to the hospital with Parkinson's disease symptoms."

O'Malley found that the toxin stopped the movement of mitochondria in the axon in 30 minutes. The railroad still functioned, shipping other cargo to the end of the axon. But most mitochondria either stopped moving or were headed for the cell body instead of the axon.

O'Malley suspected that this meant the mitochondria were damaged by the changes caused by the toxin and being shipped back to the cell body for repair. Additional tests supported this theory, showing that the mitochondria had lost their ability to maintain their membrane potential, a measure of mitochondrial fitness.

The specificity of this toxin for dopamine-producing cells is reinforced by the finding that other types of nerve cells did not have problems transporting mitochondria after toxin exposure. In a comparison between different nerve cell types, O'Malley found mitochondria in dopamine-producing nerve cells are smaller in size and travel three times slower. But she can't yet definitively say that these distinctions play a role in the problems caused by the toxin.

Scientists screened several compounds to see if they could block the toxin's effects. Only two antioxidants worked, glutathione and N-acetyl cysteine. The latter compound has already been shown to be effective in animal models of Parkinson's disease and is used as a treatment for other disorders in patients.

O'Malley is currently studying whether two genes linked to Parkinson's disease affect mitochondria damaged by the toxin.

"We're going to continue to look for specific differences in these cells that might help scientists develop better treatments," O'Malley says.


'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Related medicine news :

1. Researchers observe disruptions of daily rhythms in Alzheimers patients brains
2. Study: Mechanomyography to be accurate in detecting nerves during minimally invasive spine surgery
3. New UCSF Studies Reveal that Age-Related Nerve Decline is Associated with Inflammation and Differs by Gender
4. $1.9 million grant to help UCF find multiple sclerosis nerve-ana
5. In breakthrough, nerve connections are regenerated after spinal cord injury
6. Scientists find link in humans between nerve cell production, memory
7. Smoked Marijuana May Ease Chronic Nerve Pain
8. Burning pain and itching governed by same nerve cells
9. Nerve Zap to Kidneys Might Ease Stubborn Hypertension
10. Nerve Tissue Cancer More Often Fatal for Non-White Kids
11. Malfunctioning gene associated with Lou Gehrigs disease leads to nerve-cell death in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/17/2017)... ... 17, 2017 , ... Smiles by Seese is a comprehensive family dental ... Seese leads the practice as a skilled and highly credentialed dentist who is qualified ... serves patients of all ages with excellence in general, restorative, and cosmetic dentistry ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... ... February 17, 2017 , ... Qualis Health, one ... in the 8th Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare ... is recognized across multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... executives and focusing on all facets of clinical trial planning and management. Pharmica ... patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were able ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... NEW YORK , Feb. 17, 2017 /PRNewswire/ ... announced today the partnership of their 3D body ... in healthcare IT.  The new integration will be ... on an interactive model of the human body. ... data saves clinicians time, while also increasing the ...
(Date:2/16/2017)... , Feb. 16, 2017 Absorption Systems, ... and medical devices, is pleased to announce that its ... been selected as a winner of the 2017 Executive ... Magazine and recognizes driven executives for their creative ... ethic. The awards ceremony and celebration is on March ...
(Date:2/16/2017)... (NYSE: DVA ) today announced results for the ... Net income attributable to DaVita Inc. for the quarter and ... per share and $880 million, or $4.29 per share, respectively. ... for the quarter and year ended December 31, 2016, excluding ... per share, and $789 million, or $3.85 per share, respectively. ...
Breaking Medicine Technology: